Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2008-06-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.0711942105PMID 18523003PMCID PMC2430364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1

  2008cited by this paper
• A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza.

  2007cited by this paper
• Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection

  2007cited by this paper
• Drug Insight: aminosalicylates for the treatment of IBD

  2007cited by this paper
• Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans

  2007cited by this paper
• Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza

  2007cited by this paper
• Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza

  2007cited by this paper
• A question of self‐preservation: immunopathology in influenza virus infection

  2007cited by this paper
• Role of Host Cytokine Responses in the Pathogenesis of Avian H5N1 Influenza Viruses in Mice

  2006cited by this paper
• Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

  2006influential reference
• Avian Influenza Virus Infections in Humans

  2006cited by this paper
• Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice

  2006cited by this paper
• Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus

  2005cited by this paper
• WRITING COMMITTEE OF THE WORLD HEALTH ORGANIZATION (WHO) CONSULTATION ON HUMAN INFLUENZA A/H5. AVIAN INFLUENZA A (H5N1) INFECTION IN HUMANS

  2005cited by this paper
• Avian influenza A (H5N1) infection in humans.

  2005cited by this paper
• Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

  2005cited by this paper
• Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

  2005influential reference
• Contrasting Effects of Cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the Host Response to Influenza A Viral Infection1

  2005cited by this paper
• Preclinical evaluation of the nonsteroidal anti‐inflammatory agent celecoxib on malignant mesothelioma chemoprevention

  2004cited by this paper
• Re-emergence of fatal human influenza A subtype H5N1 disease

  2004influential reference
• Effect of 5-aminosalicylic acid on radiation-induced micronuclei in mouse bone marrow.

  2003cited by this paper
• Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses

  2001cited by this paper
• 5-Aminosalicylate stimulates phospholipase D activity in macrophages.

  2001cited by this paper
• The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.

  2000cited by this paper
• Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation

  2000influential reference
• Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.

  1998cited by this paper
• Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.

  1998cited by this paper
• Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase)

  1994cited by this paper

• The dual functions of a nor-sesquiterpene-triazole derivative against influenza A viruses through the activation of the Nrf2/HO-1 signaling pathway and interaction with hemagglutinin.

  2026cites this paper
• Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains.

  2026cites this paper
• Antivirals for Novel Influenza A Virus Infections.

  2025cites this paper
• Immune responses to avian influenza viruses in chickens.

  2025cites this paper
• Modeling viral shedding and symptom outcomes in oseltamivir-treated experimental influenza infection

  2025cites this paper
• Clinical trial of molnupiravir with or without an oral immune stimulant as a first-line treatment of feline infectious peritonitis

  2025cites this paper
• Host Immunomodulatory Interventions in Severe Influenza.

  2025cites this paper
• Reverse genetics-derived cattle H5N1 virus from Clade 2.3.4.4b shows enhanced systemic infectivity and pathogenicity than an older Clade 1 H5N1 virus in BALB/c mice

  2025cites this paper
• Influenza and the gut microbiota: A hidden therapeutic link

  2024cites this paper
• Evaluation of Anti-inflammatory Effects of Naproxen on Pro-inflammatory Cytokines in COVID-19 Patients

  2024cites this paper
• Comparison of Antiviral Immune Responses in Healthy Cats Induced by Two Immune Therapeutics

  2024cites this paper
• Pyrogallol protects against influenza A virus‐triggered lethal lung injury by activating the Nrf2–PPAR‐γ–HO‐1 signaling axis

  2024cites this paper
• Effects of Extended-Release Buprenorphine on Mouse Models of Influenza.

  2023cites this paper
• Sodium taurocholate hydrate inhibits influenza virus replication and suppresses influenza a Virus-triggered inflammation in vitro and in vivo.

  2023cites this paper
• Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality

  2023cites this paper
• Deep variational graph autoencoders for novel host-directed therapy options against COVID-19

  2022cites this paper
• Mimicking Gene–Environment Interaction of Higher Altitude Dwellers by Intermittent Hypoxia Training: COVID-19 Preventive Strategies

  2022cites this paper
• Preclinical and clinical developments for combination treatment of influenza

  2022cites this paper
• Effects of Buprenorphine Treatment on Influenza Pathogenesis in the Ferret (Mustela putorius furo).

  2022cites this paper
• Retrospective Survival Analysis of Cats with Feline Infectious Peritonitis Treated with Polyprenyl Immunostimulant That Survived over 365 Days

  2022cites this paper
• Influenza antivirals and their role in pandemic preparedness.

  2022cites this paper
• Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants

  2022influential citation
• Peptidic defective interfering gene nanoparticles against Omicron, Delta SARS-CoV-2 variants and influenza A virus in vivo

  2022cites this paper
• Simultaneous therapeutic targeting of inflammation and virus ameliorates influenza pneumonia and protects from morbidity and mortality

  2022cites this paper
• A Deep Integrated Framework for Predicting SARS-CoV2–Human Protein-Protein Interaction

  2022cites this paper
• A trifunctional peptide broadly inhibits SARS-CoV-2 Delta and Omicron variants in hamsters

  2022cites this paper
• Futurology and monitoring in the field of virology to deal with emerging diseases

  2022cites this paper
• Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development

  2022cites this paper
• Pretreatment of outer membrane vesicle and subsequent infection with influenza virus induces a long-lasting adaptive immune response against broad subtypes of influenza virus.

  2021cites this paper
• The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells

  2021cites this paper
• Effects of maoto (ma-huang-tang) on host lipid mediator and transcriptome signature in influenza virus infection

  2021cites this paper
• Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges

  2021cites this paper
• Aberrant cytokine expression in COVID-19 patients: Associations between cytokines and disease severity

  2021cites this paper
• Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means.

  2021cites this paper
• β-Cyclodextrin-containing Polymer Treatment of Cutaneous Lupus and Influenza Improves Outcomes.

  2021cites this paper
• A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 trans-Signaling and Cellular Infection with SARS-CoV-2

  2021cites this paper
• Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle

  2021cites this paper
• The roles of lipids in SARS-CoV-2 viral replication and the host immune response

  2021cites this paper
• Administration of a CXCR2 antagonist, SCH527123, together with oseltamivir suppresses NETosis and protects mice from lethal influenza and piglets from swine-influenza infection.

  2021cites this paper
• Endosomal acidification inhibitors broadly inhibit influenza virus and coronavirus in vivo

  2021cites this paper
• The role of influenza A virus-induced hypercytokinemia

  2021cites this paper
• Targeting tumour necrosis factor to ameliorate viral pneumonia

  2021cites this paper
• Immunopathogenesis and treatment of cytokine storm in COVID-19

  2021cites this paper
• COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies

  2020cites this paper
• Use of Nonsteroidal Anti-inflammatory Drugs for COVID-19 Infection: Adjunct Therapy?

  2020cites this paper
• Famotidine with Celecoxib Adjuvant Therapy on Hospitalized COVID-19 Patients: A Case Series

  2020cites this paper
• Lapiferin protects against H1N1 virus-induced pulmonary inflammation by negatively regulating NF-kB signaling

  2020cites this paper
• SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients

  2020cites this paper
• Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study

  2020cites this paper
• A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2

  2020cites this paper
• Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target

  2020cites this paper
• One hundred years of (influenza) immunopathology.

  2020cites this paper
• A broad-spectrum virus- and host-targeting antiviral peptide against SARS-CoV-2 and other respiratory viruses

  2020cites this paper
• Galectin-1 Ameliorates Influenza A H1N1pdm09 Virus-Induced Acute Lung Injury

  2020cites this paper
• Global trends in coronavirus research at the time of Covid-19: A general bibliometric approach and content analysis using SciMAT

  2020cites this paper
• Attenuating influenza a virus infection by heparin binding EGF-like growth factor

  2020cites this paper
• Predicting potential drug targets and repurposable drugs for COVID-19 via a deep generative model for graphs

  2020cites this paper
• Nuclear-Targeting Delivery of CRISPRa System for Upregulation of β-Defensin against Virus Infection by Dexamethasone and Phenylalanine Dual-Modified Dendrimer

  2020cites this paper
• Safety and potential efficacy of cyclooxygenase‐2 inhibitors in coronavirus disease 2019

  2020cites this paper
• Coronavirus Disease (COVID-19–SARS-CoV-2) and Nutrition: Is Infection in Italy Suggesting a Connection?

  2020cites this paper
• Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study

  2020cites this paper
• Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

  2020cites this paper
• UFMylation inhibits the proinflammatory capacity of interferon-γ–activated macrophages

  2020cites this paper
• Celebrex adjuvant therapy on COVID-19: An experimental study

  2020cites this paper
• ROS induced by spring viraemia of carp virus activate the inflammatory response via the MAPK/AP-1 and PI3K signaling pathways.

  2020cites this paper
• Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing

  2020cites this paper
• COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns

  2020cites this paper
• COVID-19 Usurps Host Regulatory Networks

  2020cites this paper
• Influenza Virus Neuraminidase Engages CD83 and Promotes Pulmonary Injury

  2020cites this paper
• Sinensetin suppresses influenza a virus-triggered inflammation through inhibition of NF-κB and MAPKs signalings

  2020cites this paper
• Erucic acid from Isatis indigotica Fort. suppresses influenza A virus replication and inflammation in vitro and in vivo through modulation of NF-κB and p38 MAPK pathway

  2019cites this paper
• Exploring Inflammasome Expression and Activation Using Novel Reporter Mice

  2019cites this paper
• Every 10-fold increase in viral load results in 26% more patient deaths: a correlation analysis

  2019cites this paper
• Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and meta‐analysis

  2019cites this paper
• Combination therapy targeting platelet activation and virus replication protects mice against lethal influenza pneumonia.

  2019cites this paper
• SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target

  2019cites this paper
• Development of effective anti-influenza drugs: congeners and conjugates – a review

  2019cites this paper
• Influenza – jeder kennt die „Grippe“ und doch wird sie immer noch unterschätzt

  2019cites this paper
• The Establishment and Validation of the Human U937 Cell Line as a Cellular Model to Screen Immunomodulatory Agents Regulating Cytokine Release Induced by Influenza Virus Infection

  2019cites this paper
• Polygalasaponin F treats mice with pneumonia induced by influenza virus

  2019cites this paper
• Targeting cellular nuclear export to inhibit influenza A virus replication

  2018cites this paper
• Antiviral agents targeting the influenza virus: a review and publication analysis

  2018cites this paper
• Peramivir conjugates as orally available agents against influenza H275Y mutant.

  2018cites this paper
• (+)‑pinoresinol‑O‑β‑D‑glucopyranoside from Eucommia ulmoides Oliver and its anti‑inflammatory and antiviral effects against influenza A (H1N1) virus infection.

  2018influential citation
• A systems and treatment perspective of models of influenza virus-induced host responses

  2018cites this paper
• Prostaglandin E2-Mediated Impairment of Innate Immune Response to A(H1N1)pdm09 Infection in Diet-Induced Obese Mice Could Be Restored by Paracetamol

  2018cites this paper
• Treating Influenza Infection, From Now and Into the Future

  2018cites this paper
• Feline calicivirus- and murine norovirus-induced COX-2/PGE2 signaling pathway has proviral effects

  2018cites this paper
• Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.

  2018cites this paper
• Viral Sepsis in Children

  2018cites this paper
• Differentiated human airway organoids to assess infectivity of emerging influenza virus

  2018influential citation
• The role of adjuvant immunomodulatory agents for treatment of severe influenza

  2018influential citation
• Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza

  2018cites this paper
• Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice

  2018cites this paper
• Combined effect of anti‐high‐mobility group box‐1 monoclonal antibody and peramivir against influenza A virus‐induced pneumonia in mice

  2018cites this paper
• Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration

  2018cites this paper
• Cappariloside A shows antiviral and better anti‐inflammatory effects against influenza virus via regulating host IFN signaling, in vitro and vivo

  2018cites this paper
• Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret).

  2017cites this paper
• An efficient, room temperature, oxygen radical anion (O2•−) mediated, one-pot, and multicomponent synthesis of spirooxindoles

  2017cites this paper
• Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus

  2017cites this paper